Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer
Carcinoma of the breast is the second leading cause of malignant pleural effusions. This study reports on the efficacy of mitoxantrone as a sclerosing agent in patients with breast cancer who had a pleural effusion as a direct consequence of metastatic disease.
Patients and methods
Over a 5-year period, 114 patients with a known breast malignancy and having recurrent symptomatic pleural effusion referred for chest tube drainage and sclerotherapy were considered eligible. They had received no prior intrapleural therapy and had a predicted survival of >1 month. All of them underwent pleural drainage and chemical pleurodesis with mitoxantrone. Survival, complications and response to pleurodesis according to clinical and radiographic criteria were recorded. The data are expressed as the mean ± standard error of the mean (SEM) and the median. The χ2 test was used for statistical analysis. To assess the prognostic value of Karnofsky's performance status score a Cox proportional hazards model was used.
The mean age of the patients was 53.5 ± 2.1 years. Effusion occurred after 38.2 ± 6.2 months (range: 1–229 months) after the diagnosis. Ipsilateral effusion was seen in 73%, contralateral in 20% and bilateral in 7%. Forty patients (35%) had pleural effusion as the first evidence of recurrence. The mean volume of effusion drained was 1020 ± 125 ml and the chest tube was removed within 5 days in 82% of patients. Side effects of chemical pleurodesis included mainly fever, chest pain, nausea and vomiting. At 30 days 64 patients (56.3%) had a complete response (CR) and 30 patients (26.3%) partial response (PR) to pleurodesis (overall response: 82.6%). At 60 days the overall response was 78.5% (CR:53.5%, PR: 25%). The mean survival was 15.6 ± 2 months. Karnofsky's performance status score was found to be a statistically significant predictor. Patients with Karnofsky's performance status score >70 had a median survival of 513 days, as opposed to a median survival of only 63 days for patients with a Karnofsky's performance status score <30.
Mitoxantrone is effective in the treatment of malignant pleural effusion due to breast carcinoma with relatively low local or systemic toxicity. Karnofsky's performance status score at the time of pleurodesis is predictive of survival.
- Statement of the American Thoracic Society: Management of malignant pleural effusions. Am J Respir Crit Care Med 2000, 162:1987–2001.
- Hsu C: Cytologic detection of malignancy in pleural effusion: a review of 5255 samples from 3811 patients. Diagn Cytopathol 1987, 3:8–12. CrossRef
- Apfelstaedt JP, Muller AG: Breast cancer complicated by pleural effusion. J Surg Oncol 1995, 58:173–175. CrossRef
- Evans TR, Stein RC, Pepper JR, Gazet JC, Ford HT, Coombes RC: A randomized prospective trial of surgical against medical tetracycline pleurodesis in the management of malignant pleural effusions secondary to breast cancer. Eur J Cancer 1993, 29:316–319. CrossRef
- Karnofsky DA, Abelmann WH, Craver LF, Burchenal KM: The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948, 1:634–656. CrossRef
- Testa MA, Simonson DC: Assesment of quality-of-life outcomes. N Engl J Med 1996, 334:835–840. CrossRef
- Bouros D, Froudarakis M, Siafakas N: Pleurodesis - everything flows. Chest 2000, 118:577–579. CrossRef
- Sahn SA: Pleural effusion in lung cancer. Clin Chest Med 1993, 14:189–200.
- Johnston WW: The malignant pleural effusion: a review of cytopathologic diagnosis of 584 specimens from 472 consecutive patients. Cancer 1985, 56:905–909. CrossRef
- Antunes G, Neville E, Duffy J, Ali N: BTS guidelines for the management of malignant pleural effusions. Thorax 2003, 58:29–38. CrossRef
- Hausheer FH, Yarbro JW: Diagnosis and treatment of malignant pleural effusion. Cancer Metastasis Rev 1987, 6:23–40. CrossRef
- Patz E, McAdams P, Erasmus J, Goodman P, Culhane D, Gilkeson R, Herndon J: Sclerotherapy for malignant pleural effusions. A prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 1998, 113:1305–1311. CrossRef
- Seaton KG, Patz EF Jr, Goodman PC: Palliative treatment of malignant pleural effusions: value of small-bore catheter thoracostomy and doxycycline sclerotherapy. A JR Roentgenol 1995, 164:589–591.
- Rosato FE, Wallach MW, Rosato EF: The management of malignant pleural effusion from breast cancer. J Surg Oncol 1974, 6:441–449. CrossRef
- Raju R, Kardinal C: Pleural effusion in breast carcinoma. Analysis of 122 cases. Cancer 1981, 48:2524–2527. CrossRef
- Fentiman I, Millis R, Sexton S, Hayward J: Pleural effusion in breast cancer: A review of 105 cases. Cancer 1981, 47:2087–2092. CrossRef
- Yeste L, Murillo J, Galbis JM, Torre W: [Thoracic metastasis of breast carcinoma. Current status]. Rev Med Univ Navarra 2003, 47:17–21. Spanish
- Konikov N, Bleisch V, Piskie V: Prognostic significance of cytologic diagnoses of effusions. Acta Cytol 1966, 10:335–339.
- Anderson CB, Philpott GW, Ferguson TB: The treatment of malignant pleural effusions. Cancer 1974, 3:916–922. CrossRef
- Martini N, Bains MS, Beattie EJ: Indications for pleurectomy in malignant effusion. Cancer 1975, 35:734–738. CrossRef
- Chernow B, Sahn SA: Carcinomatous involvement of pleura: an analysis of 96 patients. Am J Med 1977, 63:695–702. CrossRef
- Saisho S, Saeki T, Takashima S, Aogi K, Ohsumi S: Local administration of adriamycin (ADM) for malignant pleural and pericardial effusion in breast cancer. Gan To Kagaku Ryoho 2003, 30:2063–2068.
- Bilaceroglu S, Cagirici U, Perim K: Corynebacterium parvum pleurodesis and syrvival is not significantly influenced by pleural pH and glucose level. Monaldi Arch Chest Dis 1998, 53:14–22.
- Foresti V, Scolari N, Villa A: Malignant pleural effusions: meaning of pleural-fluid pH determination. Oncology 1990, 47:62–64. CrossRef
- Burrows C, Mathews C, Colt H: Predicting survival in patients with recurrent symptomatic malignant pleural effusions. An assessment of the prognostic values of physiologic, morphologic and quality of life measures of extent of disease. Chest 2000, 117:73–78. CrossRef
- Hartman DL, Gaither JM, Kesler KA: Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993, 105:743–748.
- Gravelyn TR, Michelson MK, Gross BH: Tetracycline pleurodesis for malignant pleural effusions: a 10-year retrospective study. Cancer 1987, 59:1973–1977. CrossRef
- Goff BA, Mueller PR, Muntz HG: Small chest tube drainage followed by bleomycin sclerosis for malignant pleural effusions. Obstet Gynecol 1993, 81:993–996.
- Moffett MJ, Ruckdeschel JC: Bleomycin and tetracycline in malignant pleural effusions: a review. Semin Oncol 1992, 19:59–62.
- Ostrowski MJ: Intracavitary therapy with bleomycin for the treatment of malignant pleural effusions. J Surg Oncol Suppl 1989, 1:7–13. CrossRef
- Ruckdeschel JC, Moores D, Lee JY, Einhorn LH, Momdelbaum I, Koeller J, Weiss GR, Losada M, Koller JH: Intrapleural therapy for malignant pleural effusions: a randomised comparison of bleomycin and tetracycline. Chest 1991, 100:1528–1535. CrossRef
- Rehse DH, Aye RW, Florence MG: Respiratory failure following talc pleurodesis. Am J Surg 1999, 177:437–440. CrossRef
- Marom EM, Patz EF, Erasmus JJ, McAdams HP, Goodman PC, Herndon JE: Malignant pleural effusions: treatment with small-bore catheter thoracostomy and talc pleurodesis. Radiology 1999, 210:277–281.
- Fingar BL: Sclerosing agents used to control malignant pleural effusions. Hosp Pharm 1992, 27:622–628.
- Robertson JF, Williams MR, Todd JH, Blamey RW: Mitoxantrone is a useful palliative therapy in advanced breast cancer. Am J Clin Oncol 1989, 12:393–396. CrossRef
- Brufman G, Haim N, Ben-Baruch N, Sulkes A: Second line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer. J Chemother 1993, 5:43–46.
- Vargas FS, Teixeira LR, Antonangelo L, Silva lM, Strauz CM, Light RW: Acute and chronic pleural changes after intrapleural instillation of mitoxantrone in rabbits. Lung 1998, 176:227–236. CrossRef
- Seitzer D, Musch E, Kuhn W: Die locale behandlung maligner pleuraergusse bei gynakologischen tumoren. Zent Bl Gynakol 1990, 112:757–765.
- Musch E, Loos U, Mackes KG: Intrapleural mitoxantrone in the treatment of malignant pleural effusions. In: Advances in Regional Cancer Therapy 1 Edition (Edited by: Kreidler H, Link KH, Aigner RB). Basel: Karger 1988, 184–189.
- Maiche AG, Virkunnen P, Kontkanen T, Mokkynen K, Porkka K: Bleomycin and mitoxantrone in the treatment of malignant pleural effusions. Am J Clin Oncol 1993, 16:50–53. CrossRef
- Van Belle AF, Velde GPM, Weuters EFM: Chemical pleurodesis with mitoxantrone in the management of malignant effusion. Eur J Cancer 1998, 34:206–207. CrossRef
- Morales M, Exposito MC: Intrapleural mitoxantrone for the palliative care treatment of malignant pleural effusions. Support Care Cancer 1995, 3:147–149. CrossRef
- Groth G, Gatzmeier U, Haussingen K, Heckmayr M, Magnussen H, Neuhauss R, Pavel JV: Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann Oncol 1991, 2:213–215.
- Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
World Journal of Surgical Oncology
- Online Date
- May 2004
- Online ISSN
- BioMed Central
- Additional Links
- malignant pleural effusion
- breast cancer
- Karnofsky performance status